ReachMD

Dr. Philip Schein is widely regarded as a leading international authority in the treatment of cancer. He is a visiting professor in cancer pharmacology at the University of Oxford in England and the president of The Schein Group, which provides consultative services to the pharmaceutical industry. Dr. Schein served as a Senior Investigator and Head of the Clinical Pharmacology Section of the Medicine Branch, National Cancer Institute. His next appointment was at the Georgetown University School of Medicine in Washington, DC, as professor of medicine and pharmacology, chief of medical oncology and scientific director of the Vincent T. Lombardi Cancer Research Center. Subsequently he served as vice president of Worldwide Clinical Research and Development, and director of the Laboratory of Molecular Oncology, SmithKline & French Laboratories, where he had responsibility for all SK&F clinical research and development activities.  In 1987 Dr. Schein founded U.S. Bioscience, a publically-traded pharmaceutical company focused on cancer and AIDS, and while serving as chairman and CEO he took three products, Ethyol, Hexalen and Neutrexin, through development and regulatory approval in the US, Europe, Canada and other countries. 

Dr. Schein has held major positions in the field of Medical Oncology. He has served as president of the American Society of Clinical Oncology and he has chaired the Food and Drug Administration's Oncologic Drugs Advisory Committee. He has served as a member of the Board of Directors on the American Board of Internal Medicine, where he chaired the Medical Oncology Committee. He was appointed by President Clinton to the National Cancer Advisory Board. He has also served as co-chairman of the Gastrointestinal Cancer Tumor Study Group and was a founding member of the Japan-American, French-American Agreement and Pan American Health Organization-US Agreements on Cancer Research. In 1984, in a survey of department chairmen and clinical-program chiefs at 87 medical schools, Dr. Schein was ranked as one of the 120 best doctors in America, and one of four listed in Oncology. 

He has authored over 350 articles and texts relating to basic and clinical cancer research and drug development, and has been awarded 11 patents.  He is a recipient of numerous scientific and medical awards including the Harvey W. Wiley Medal from the FDA and the Wainwright Award for Excellence in Medical Education. Dr. Schein is a Fellow of the Royal College of Physicians of London and the Royal College of Physicians and Surgeons at Glasgow. While serving as CEO of U.S. Bioscience he was the 1992 recipient of the Delaware Valley's Entrepreneur of the Year Award in the "Emerging Company" category, and in 1995 the region's 3rd Annual Enterprise Awards designated U.S. Bioscience the "Technology Transfer Company of the Year." He has been awarded a Honorary Doctor of Science degree from Rutgers University and a Doctorate Honoris Causa from the National University of Rosario, Argentina.  He serves on the Board of Directors of Medicis, and on the scientific advisory boards of several companies in the biotechnology/pharmaceutical industry.